June 26, 2020 / 5:49 PM / 10 days ago

BRIEF-Chiasma Announces FDA Approval Of Mycapssa Capsules

June 26 (Reuters) - Chiasma Inc:

* CHIASMA ANNOUNCES FDA APPROVAL OF MYCAPSSA® (OCTREOTIDE) CAPSULES, THE FIRST AND ONLY ORAL SOMATOSTATIN ANALOG

* CHIASMA INC - COMPANY EXPECTS MYCAPSSA TO BE COMMERCIALLY AVAILABLE IN Q4 OF 2020

* CHIASMA INC - PLANS TO SCALE-UP ITS CUSTOMER FACING TEAM IN SALES, PATIENT SERVICES & MARKET ACCESS TO ABOUT 45 EMPLOYEES

* CHIASMA INC - ‘PLANS TO PRICE MYCAPSSA COMPETITIVELY WITH FASTEST GROWING SSA IN U.S. ACROMEGALY MARKET’

* CHIASMA - APPROVAL OF MYCAPSSA BASED ON PHASE 3 CHIASMA OPTIMAL CLINICAL TRIAL OF OCTREOTIDE CAPSULES, SAFETY DATA FROM ALL PHASE 3 TRIALS OF MYCAPSSA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below